Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Receivables (2022 - 2025)

Atara Biotherapeutics' Receivables history spans 4 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Receivables fell 15.45% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 15.45%, while the annual FY2025 figure was $1.3 million, 15.45% down from the prior year.
  • Receivables reached $1.3 million in Q4 2025 per ATRA's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $40.2 million in Q4 2022 to a low of $163000.0 in Q3 2023.
  • Average Receivables over 4 years is $8.7 million, with a median of $1.3 million recorded in 2024.
  • The largest YoY upside for Receivables was 8926.2% in 2024 against a maximum downside of 95.65% in 2024.
  • A 4-year view of Receivables shows it stood at $40.2 million in 2022, then fell by 15.2% to $34.1 million in 2023, then plummeted by 95.65% to $1.5 million in 2024, then decreased by 15.45% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Receivables are $1.3 million (Q4 2025), $1.9 million (Q3 2025), and $8.9 million (Q1 2025).